This article discusses the advantages and pitfalls of testing neuroprotective treatment strategies in patients suffering from optic neuritis.
INTRODUCTION
Optic neuritis has been rediscovered as a model disease for human treatment trials in demyelinating diseases [1] [2] [3] . With few exceptions the multiple sclerosis (MS) treatment trial community had turned a blind eye on MS associated optic neuritis (MSON) since completion of the influential optic neuritis treatment trial (ONTT). What has triggered the renewed interest in optic neuritis for human treatment trials?
Treatment of inflammatory disease activity MS is effective. Disease modifying treatments (DMTs) reduce the chance for a new relapse by about 30-70% depending on choice of treatment [4] . Evidence of DMT to halt disease progression has been less convincing.
The attraction of optic neuritis as a model disease for neuroprotective treatment trials has coincided with the availability of new clinical and paraclinical outcome measures for vision [5] . The expectations are that a treatment trial in MSON can be conducted fast with highly accurate outcome measures. A successful MSON trial can be a promising stepping stone for neuroprotective treatment strategies in MS in general.
OPTIC NEURITIS IN MULTIPLE SCLEROSIS
The presentation of MSON is that of peri-orbital/ retro-orbital pain worsening with eye movements which is associated with loss of vision [6] . Recovery is usually good. Residual visual symptoms are dyschromatopsia and reduced low contrast visual
RELEVANT TRIAL DESIGN IMPLICATIONS FROM THE DIAGNOSTIC WORK-UP OF ACUTE OPTIC NEURITIS
Ahmed Toosy and Tom Jenkins have reviewed the general assessment of patients with MSON in this issue. In practice the diagnosis of acute optic neuritis within days after onset is more challenging than after about 3 months [6] , as many of the classical symptoms and signs may not yet have developed. Predicting the 5% of patients with optic neuritis who will have a poor visual outcome at presentation is challenging [7] and contamination of neuroprotective ONTTs with these patients is a real possibility. Exclusion of other aetiologies of autoimmune visual loss in the acute phase requires testing for auto-antibodies [8 & ,9] .
OUTCOME MEASURES FOR NEUROPROTECTIVE TREATMENT TRIALS IN OPTIC NEURITIS
The key pathological features used as an outcome measure in MSON are demyelination and axonal loss. Currently, demyelination is recorded using electrophysiology. Axonal loss in the retina is assessed with optical coherence tomography (OCT). Axonal loss in the optic nerve, optic tracts and optic radiations is assessed by MRI.
Visual function is assessed with high and low contrast visual acuities, contrast sensitivity, colour vision tests and visual field tests [5, 6] .
Visual Quality of Life is documented with validated patient questionnaires. The 25-Item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) has been extended by a neuroophthalmology supplement [10] .
Remyelination: Inflammation at the onset of MSON is sufficient to cause conduction block in the optic nerve. Inflammation precedes demyelination. Because the nadir of demyelination is not known, assessment of demyelination/remyelination is difficult. It is not known at which time point after onset of acute MSON visual function and electrophysiology are best recorded. This will remain a tricky problem for ONTT design.
A clinical outcome measure for remyelination may be presence of Uhthoff phenomenon during the recovery phase from MSON [11] .
Electrophysiology
The electrophysiological tests are of particular value in studies evaluating therapy [3, 12] . The International Society for Clinical Electrophysiology of Vision (ISCEV) (www.iscev.org/standards/proceduresguide.html) specifies the standards, gives recommendations and provides guidelines on testing [13 & ]. For ONTTs, relevant tests to consider are the Pattern Appearance Visually Evoked Cortical Potential (VEP) and the Pattern Electroretinogram (PERG) [6, 14] . Demyelination of the optic pathways results in delay of the VEP P100 amplitude. The accepted wisdom is that recovery of conduction velocity indicates remyelination. The challenge is to capture the right moment.
The PERG permits early detection of retinal pathology both at the level of retinal ganglion cells (N95 component) and proximally (P50 component) in affected eyes [15] . The multifocal ERG (mfERG) permits for more detailed spatial analysis and shows a reduced optic nerve head component (ONHC) response following demyelination [16] .
Optical coherence tomography
Retinal OCT has become one of the best validated and most sensitive outcome measures for neurodegeneration following MSON [5, 6, 17] . The need for standardized OCT acquisition procedures, quality control and reporting guidelines has been recognized [18,19,20 & ]. RNFL: The thickness of the peripapillary retinal nerve fibre layer (pRNFL) is a highly robust longterm outcome measure for MSON treatment trials.
KEY POINTS
Patients with acute optic neuritis will want to know about vision restoring treatment options.
Current treatment trials investigate possibilities to halt inflammation, to promote remyelination and to reduce neurodegeneration.
The efficacy of these treatment strategies can be assessed with validated outcome measures accurately capturing structure and function of the visual system.
The effect size of reviewed successful proof-of-principal studies remains too small to have a realistic chance to translate into clinical practice.
In clinical practice an increase of treatment with oral rather than intravenous corticosteriods is likely in view of recent noninferiority trials.
Following optic neuritis there is substantial axonal damage [7] . At presentation this can be masked by presence of optic disc oedema [21] . Longitudinal studies demonstrate that atrophy of the pRNFL becomes manifest within about 3 months and plateaus after about 1 year [2, 22 && ]. Atrophy of the pRNFL after MSON in a meta-analysis of cross-sectional studies averaged at 20 mm (95% CI 18-23 mm) using time domain OCT [23] . The annual atrophy rate of the pRNFL was highest in patients with MSON and a short disease duration [24, 25] .
GCIPL: The ganglion cell/inner plexiform layer (GCIPL) thickness is a valuable early response outcome measure. The GCIPL has the important advantage that optic disc oedema does not reach the macula, hence atrophy can be detected about 2 months earlier than in the RNFL [22 && ]. INL: The inner nuclear layer (INL) is a promising outcome measure for inflammation. In MS, there is evidence that INL volume changes are related to inflammatory disease activity and respond to DMT [26 & ]. These rapid transient volume changes were hypothesized to be caused by fluid shift in an impaired retinal glymphatic system [27] . The glymphatic system has originally been described for the brain and describes a paravascular pathway for cerebrospinal fluid and interstitial fluid exchange. The system has similarities with the lymphatic system and was termed 'g'lymphatic because of the importance of glial cells. Thickening of the INL following MSON has been observed. Anti-inflammatory treatment in MSON may therefore be reflected in normalization of INL volume.
MRI
ONTTs may include MRI for diagnostic reasons, to exclude other relevant comorbidity and for safety reasons. Coronal are recommended and should not take much more than 10 min to acquire under optimal conditions, including T2-weighted images with fat suppression (e.g. STIR, SPIR) and T1-weighed images before and after contrast administration [6, 28, 29] . For assessment of tissue integrity a range of additional techniques are available, such as high resolution 3D T2-weighted (CISS) images for the visualization and volume measurements of the optic nerve and diffusion tensor imaging (DTI) [17, 30] . There is experimental and human post-mortem evidence to suggest a role of DTI and high-field MRI for assessment of remyelination [31] . Longitudinal studies will need to take into account the use of different scanners over time [32 & ]. Figure 1 gives an overview on compounds and strategies reviewed. The primary and secondary outcome measures have been summarized in Table 1 .
NEUROPROTECTIVE TREATMENT TRIALS
Adrenocorticotropic hormone: One phase 0 (NCT01987167) and one phase 4 (NCT01838174) investigate the neuroprotective role of adrenocorticotropic hormone (ACTH), synonymous corticotropin in MSON. It is hypothesized that melanocortin-mediated anti-inflammatory effects of ACTH will be neuroprotective in MSON. Patients in one trial (NCT01838174) also receive intravenous methylprednisolone therapy (IVMP).
Amiloride: Two phase 2 trials (NCT01879527, NCT01802489) test for the neuroprotective effect of amiloride in MSON [33] . Amiloride is approved as a diuretic. Amiloride blocks the acid sensing ion channel 1 (ASIC1) that controls Na 2þ and Ca 2þ fluxes. Blockage of cytotoxic cellular overload with Ca 2þ could be neuroprotective in MSON. The primary outcome measure was the scanning laser polarimetry (GDx)-derived pRNFL thickness in addition to the OCT measured pRNFL thickness. The GDx methodology relies on birefringence of the RNFL [23] . Birefringence is related to the structure of dominant axonal filaments such as the neurofilament protein. Because neurofilament protein composition changes with axonal injury and precedes axonotmesis it had been hypothesized that changes of RNFL birefringence may represent the earliest sign of axonal degeneration in MSON [23] . The amiloride trial in MSON has however been reported as negative with regard to the primary outcome measures [34] . What can be learned from the trial, however, is that the baseline GDx pRNFL thickness was less affected by optic disc oedema compared with the OCT-derived pRNFL thickness.
Unexpectedly, one of the secondary outcome measures, the change of VEP latencies, were found to be delayed by 12.81 ms in the treatment arm (27.27 ms) if compared to placebo (14.45 ms, P ¼ 0.0043) at 6 months. This may imply that amiloride impedes remyelination.
It should also be remembered that patients were recruited up to 28 days (mean 14 days) of onset which may have been too late.
Atacicept: One phase 2 trial (2007-003925-26) gave the recombinant fusion protein atacicept. Atacicept inhibits B-cells. Mature B-cells and plasma cells are more likely to blocked then by memory B-cells and progenitor cells. Corticosteroids may be given optionally to treat the initial optic neuritis event. The trial was prematurely stopped. Disease activity was higher in the treatment arm [35] . The data available showed a minimal effect of atacicept on pRNFL atrophy.
Cholecalciferol: There is evidence that patients with MSON and low vitamin D levels have more severe atrophy of the pRNFL and ganglion cell layer [36] . There is one ongoing phase 3 (2010-018498-39) testing the potential neuroprotective effect of cholecalciferol in acute MSON.
Clemastine: An exciting translational research line lead to the discovery of clemastine fumarate as a compound stimulation remyelination [37] . [38] . An important recent trial demonstrated the noninferiority of oral high-dose (1000 mg) methylprednisolone for 3 days compared to IVMP (1000 mg) [39
&&
]. No placebo-controlled trial of oral corticosteroids had been published since 1999 according to the last systematic Cochrane review [40] . Recently, a randomized single-blinded clinical trial suggests no inferiority of oral (1250 mg oral prednisone 1 ) compared with intravenous (1000 mg methylprednisolone) corticosteroids [41] . The treatment groups were matched for demographic factors including ethnicity and MSON was the first demyelinating event in 14/23 (60.9%) in the oral group and 16/23 (69.9%) in the intravenous group. A potential inclusion bias may be discussed with baseline VA being worse (20/200) in the oral compared with 20/100 in the intravenous group (P ¼ 0.061), but there was no statistically significant difference at the 6 months follow up (20/33 compared to 20/20, respectively, P ¼ 0.032). The delay from onset to treatment has not been presented.
There is anecdotal evidence that hyperacute treatment with corticosteroids in MSON may be neuroprotective [42, 43] . One phase 4 trial (2012-002628-34) evaluates early treatment with highdose IVMP.
Erythropoietin: The glycoprotein hormone erythropoietin (EPO) boosts red blood cell production. Consistent with experimental evidence for neuroprotective properties of EPO, a phase 2 MSON treatment trial (NCT00355095) was successfully concluded [44] . Treatment with EPO led to significantly less pRNFL atrophy (OCT), optic nerve atrophy (MRI) and better VEP latencies. Patients in this trial also received IVMP. The median time from onset to treatment was 4 days for EPO/IVMP and 2 days later for IVMP. Whether or not early treatment with IVMP may have caused a bias is not known. A follow-up phase 3 trial (NCT01962571) is ongoing [45] .
Fingolimod: A phase 2/3 trial with fingolimod (2011-004787-30) in MSON was prematurely terminated due to poor recruitment.
Minocycline: Two phase 2 trials (NCT01073813, 2011-001589-16) examine the neuroprotective effect of the tetracycline antibiotic minocycline in MSON. Minocycline has multilevel anti-apoptotic properties and reduces glutamate toxicity.
Opicinumab: Differentiation of oligodendrocytes is inhibited by membrane glycoproteins to which LINGO-1 belongs [3] . A phase 2 trial with opicinumab (NCT01721161) has completed. Treatment with opicinumab was associated with an increased VEP latency recovery (22.24 ms) compared with placebo (14.69, P ¼ 0.0504). There was no effect on the pRNFL (À11.75 vs. 15.66 mm), GCIPL (À9.9 vs. À11.05) or low contrast visual acuity. The trial has been extended (NCT02657915).
Phenytoin: There is good translational and preclinical data on the neuroprotective effect of ion channel blocking agents [34] . A phase 2 trial with the antiepileptic drug phenytoin was positive for the primary outcome measure. There was significantly less atrophy (À7.15 mm) of the pRNFL in the treatment group if compared with the placebo group [46 & ]. Likewise, thinning of the total macular volume (À0.20 mm 3 ) was less marked in the treatment group. However, atrophy of the GCIPL, thought to be a good biomarker because less affected by the baseline disc oedema compared with the pRNFL, did not differ significantly between the treatment group and placebo [47] . Of the secondary outcome measures, blood-derived neurofilament heavy chain levels were significantly lower in patients treated with phenytoin compared with placebo [48] . None of the clinical outcome measures reached significance.
The average time from onset to randomization was 8 days in both groups. Patients were also given the option of IVMP. More patients in the treatment group received IVMP (85%) compared with the placebo group (75%).
Simvastatin: There is in-vitro, translational, preclinical and clinical evidence for favourable immunological effects and neuroprotection of statins in demyelination, particularly in secondary progressive MS [48, 49] . A phase 3 trial suggested improved recovery of colour vision and VEP latency amplitude in patients treated with statins [50] . The average time from symptom onset to treatment was 12 days for statins and 15 days for placebo.
CONCLUSION
The last 2 years have seen the publication of thought-provoking data regarding the treatment of patients with MSON. Six compounds are in phase 2 and five compounds in phase 3/4. With one exception, opicinumab, all compounds have already been approved for other conditions.
Retinal OCT has clearly become the favourable structural outcome measure, being included in 13/15 (86%) of the trials. The most frequently employed functional paraclinical outcome measure is the VEP latency in 12/15 (80%) of trials. Well thought through timing of the VEP assessment is crucial to capture the moment of optic nerve demyelination. Currently, short-interval longitudinal VEP recordings may be required.
Because of the small effect size of the pRNFL and VEP latencies in the published trials, it cannot be overemphasized how important it is to have a rigorous quality control pipeline in place in order to avoid data contamination [13 & ,19,20 & ]. Ten studies detailed MRI sequences with assessment of optic nerve diameter being useful for assessment of atrophy. Likewise coronal T2-weighted images with fat suppression and coronal T1 Gd enhancing images are extremely useful for confirmation of presence and location of optic nerve inflammation. There is a plethora of exciting MRI research sequences, which investigate diffuse tissue damage.
Novel outcome measures include a biomarker for axonal degeneration, the neurofilament protein and pupillography (clemastine, NCT02521311).
The time from symptom onset to treatment initiation in MSON is still rather long compared to what has been achieved in stroke medicine. There is anecdotal evidence for a beneficial effect of hyperacute treatment. We have achieved same day treatment in the vast majority of patients presenting with transient monocular blindness at Moorfields Eye Hospital by tapping into established stroke pathways. Similar efforts need to be made for MSON.
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